Clinical trial · Observational
Observational Study on GEP-and Pulm-NET Treated at FPG
Observational Study on Clinical, Laboratory, Anatomopathological and Molecular Characteristics and Their Prognostic and Predictive Value in Patients With Neuroendocrine Tumors of the Gastroenteropancreatic Tract and Pulmonary Treated at Fondazione Policlinico Agostino Gemelli (FPG)-IRCCS
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational ambispective monocentric study on the clinical, laboratory, pathological and molecular characteristics of patients suffering from gastroenteropancreatic tract and pulmonary neuroendocrine tumors and their prognostic and predictive value.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gep Net | Digestive System Neuroendocrine Tumor | ALIAS | 0.90 |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Pulmonary Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- retrospective cohort
- description
- GEP- and Pulm- NET patients referred to the U.O.C. of Medical Oncology of the FPG - IRCCS since 01/01/2010 up to the date of approval of the study.
- label
- prospective cohort
- description
- GEP- and Pulm- NET patients referred to the U.O.C. of Medical Oncology of the FPG - IRCCS starting from the date of approval of the study for the following 36 months.
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- from randomization to end of study or death event (estimed: up to 36 months).
- description
- The length of time from the date of diagnosis to death.
Secondary outcomes (1)
- measure
- Progression Free Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histological diagnosis of gastroenteropancreatic or pulmonary NET * age ≥ 18 years; * radiological evidence of resectable/locally advanced/metastatic disease; * signing of informed consent; * at least one visit following the first oncological visit. Exclusion Criteria: * absence of clinical data that allow adequate definition of survival (primary endpoint of the study); * absence of histological diagnosis; * failure to sign the informed consent.
References
Publications (0)
Data not yet available